Industry Partnerships

Unravel Biosciences is a therapeutics company that uses artificial intelligence (AI) models of patient RNA networks followed by rapid in vivo (Popup Definition: “in vivo” is a term that scientists use to describe experiments or studies that are conducted inside living organisms, such as animals, humans, or plants. It is a Latin phrase that means “within the living”) screening and clinical validation of discovered targets to develop new therapeutics. CSNK2A1 Foundation is partnering with Unravel to analyze RNA from OCNDS patient fibroblast (Popup Definition: A fibroblast is a type of cell that contributes to the formation of connective tissue, a fibrous cellular material that supports and connects other tissues or organs in the body. Fibroblasts secrete collagen proteins that help maintain the structural framework of tissues. They also play an important role in healing wounds. Obtained from a person through a simple skin biopsy, fibroblasts can be grown in the laboratory for use in genetic and other scientific studies of that individual) samples and the K198R (Popup Definition: K198R is the most common DNA variant that appears in patients with OCNDS. It means that at position 198 in the DNA, the amino acid that is normally present, “K” (lysine) is replaced with “R” (arginine), which causes issues with how the protein CK2 can function) OCNDS mouse model. The award leverages Unravel’s BioNAV™ AI prediction platform to analyze patient mutations and identify the most suitable mouse genetic model through cross-species stratification of drug response. The project will build upon previous work by Unravel in which several drug candidates that proved effective in Unravel’s SquishyWare™ in vivo models were identified.